Skip to main content

Anaplastic Pleomorphic Xanthoastrocytoma clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for
  • Experimental Combination of Dabrafenib and Trametinib After Radiation For High-Grade Glioma (brain/nervous system cancer)

    open to eligible people ages 12 months to 21 years

    This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma.

    at UC Davis UCLA UCSF

  • Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

    Sorry, in progress, not accepting new patients

    The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.

    at UCLA

Our lead scientists for Anaplastic Pleomorphic Xanthoastrocytoma research studies include .

Last updated: